Index RUT P/E - EPS (ttm) -0.14 Insider Own 1.54% Shs Outstand 77.50M Perf Week 10.16%
Market Cap 3.12B Forward P/E 65.73 EPS next Y 0.60 Insider Trans -10.41% Shs Float 76.31M Perf Month 20.77%
Income -9.27M PEG - EPS next Q 0.11 Inst Own 106.24% Short Float 4.06% Perf Quarter 22.46%
Sales 425.33M P/S 7.33 EPS this Y 135.29% Inst Trans 2.94% Short Ratio 3.98 Perf Half Y 90.34%
Book/sh 15.18 P/B 2.61 EPS next Y 67.30% ROA -0.77% Short Interest 3.10M Perf Year 51.57%
Cash/sh 3.48 P/C 11.38 EPS next 5Y - ROE -0.83% 52W Range 18.61 - 41.43 Perf YTD 43.91%
Dividend Est. - P/FCF 55.23 EPS past 5Y -10.52% ROI -0.78% 52W High -4.44% Beta 1.66
Dividend TTM - Quick Ratio 4.79 Sales past 5Y 34.42% Gross Margin 64.93% 52W Low 112.74% ATR (14) 1.67
Dividend Ex-Date - Current Ratio 5.08 EPS Y/Y TTM 79.63% Oper. Margin 2.65% RSI (14) 63.29 Volatility 4.45% 4.60%
Employees 815 Debt/Eq 0.02 Sales Y/Y TTM 23.95% Profit Margin -2.18% Recom 1.50 Target Price 43.00
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 147.47% Payout - Rel Volume 0.92 Prev Close 38.94
Sales Surprise 5.50% EPS Surprise 486.42% Sales Q/Q 28.58% Earnings Nov 06 AMC Avg Volume 780.09K Price 39.59
SMA20 7.57% SMA50 13.48% SMA200 50.01% Trades
Volume 714,947 Change 1.67%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-15-24 Initiated Wolfe Research
Outperform
$50
Oct-16-24 Initiated UBS
Buy
$43
Oct-10-24 Initiated Guggenheim
Buy
$40
Feb-23-24 Reiterated Needham
Buy
$30 → $33
Jan-18-23 Downgrade Raymond James
Outperform → Mkt Perform
Jan-05-23 Initiated Scotiabank
Sector Outperform
$33
Jan-07-22 Initiated Stephens
Overweight
$52
Nov-18-21 Resumed Goldman
Buy
$60
Jun-15-21 Initiated Raymond James
Outperform
$45
Feb-18-21 Resumed Needham
Buy
$88
Jan-28-21 Initiated Truist
Buy
$61
Nov-10-20 Initiated KeyBanc Capital Markets
Sector Weight
$48
Sep-09-20 Initiated Morgan Stanley
Underweight
$35
Jul-31-19 Initiated Lake Street
Buy
$35
Jul-02-19 Initiated Needham
Buy
$33
Nov-29-18 Downgrade Janney
Buy → Neutral
Oct-31-18 Upgrade Janney
Neutral → Buy
Nov-07-17 Downgrade Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade Janney
Buy → Neutral
Aug-31-17 Resumed BTIG Research
Buy
$13
Show Previous Ratings
Nov-07-24 10:01AM
Nov-06-24 06:10PM
05:05PM
(Associated Press Finance)
04:05PM
Nov-05-24 07:43AM
05:00PM
Loading…
Oct-30-24 05:00PM
Oct-16-24 06:43PM
Oct-09-24 05:07PM
Oct-02-24 05:02PM
08:20AM
Sep-15-24 08:45AM
Sep-06-24 07:01PM
Sep-05-24 11:31AM
Sep-04-24 04:05PM
09:50AM
05:30PM
Loading…
Aug-26-24 05:30PM
09:00AM
04:36AM
Aug-19-24 09:55AM
Aug-15-24 09:50AM
Aug-14-24 09:15AM
Aug-09-24 07:22PM
Aug-08-24 09:09AM
Aug-07-24 02:08PM
Aug-06-24 06:25PM
05:24PM
(Associated Press Finance)
04:05PM
Jul-24-24 10:57AM
Jul-19-24 12:01AM
Jul-17-24 05:00PM
04:48AM
Loading…
04:48AM
Jun-21-24 09:55AM
Jun-06-24 11:31AM
Jun-03-24 04:05PM
May-29-24 09:55AM
09:30AM
May-28-24 09:31AM
08:47AM
08:32AM
May-23-24 10:00AM
May-22-24 04:05PM
May-21-24 09:59AM
May-15-24 05:04PM
May-13-24 09:55AM
May-08-24 03:13PM
08:55AM
07:12AM
(Thomson Reuters StreetEvents)
03:48AM
May-07-24 10:55PM
06:13PM
(Associated Press Finance)
06:00PM
04:05PM
May-06-24 04:05PM
Apr-22-24 05:00PM
08:30AM
Apr-16-24 08:30AM
Apr-02-24 10:33AM
Feb-27-24 05:55PM
Feb-26-24 03:20PM
Feb-23-24 11:10AM
07:43AM
07:37AM
(Thomson Reuters StreetEvents)
Feb-22-24 06:05PM
05:03PM
(Associated Press Finance)
04:40PM
04:05PM
Feb-21-24 05:00PM
Feb-08-24 08:00AM
Feb-06-24 08:15AM
Jan-08-24 08:00AM
Dec-12-23 04:30PM
Dec-01-23 04:05PM
Nov-29-23 08:30AM
Nov-22-23 08:30AM
Nov-08-23 04:39PM
Nov-07-23 04:57PM
(Associated Press Finance)
04:05PM
04:00PM
Nov-02-23 08:15AM
Oct-27-23 08:30AM
Oct-26-23 02:50PM
Oct-17-23 08:15AM
Oct-16-23 10:43AM
Oct-12-23 09:00AM
Oct-04-23 04:05PM
Sep-28-23 04:05PM
08:15AM
Sep-27-23 09:00AM
Sep-21-23 04:05PM
Sep-07-23 04:05PM
Sep-06-23 08:15AM
Sep-02-23 06:15AM
Aug-29-23 08:15AM
Aug-22-23 08:15AM
Aug-15-23 04:15PM
Aug-08-23 06:05PM
04:55PM
04:05PM
Aug-01-23 08:15AM
Jul-19-23 05:00PM
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
EASTHAM KARIN Director Nov 19 '24 Sale 38.34 14,731 564,768 18,497 Nov 21 04:36 PM KARIN EASTHAM Director Nov 19 '24 Proposed Sale 36.71 14,731 540,775 Nov 19 04:23 PM Chambers Rebecca Chief Financial Officer Nov 12 '24 Sale 38.34 15,275 585,663 124,501 Nov 14 04:35 PM EPSTEIN ROBERT S Director Nov 12 '24 Option Exercise 8.04 15,000 120,600 59,598 Nov 14 04:35 PM EPSTEIN ROBERT S Director Nov 12 '24 Sale 38.32 15,000 574,830 44,598 Nov 14 04:35 PM ROBERT S EPSTEIN Director Nov 12 '24 Proposed Sale 38.89 15,000 583,350 Nov 12 04:29 PM REBECCA CHAMBERS Officer Nov 12 '24 Proposed Sale 38.89 15,275 594,045 Nov 12 04:29 PM JONES EVAN/ FA Director Sep 19 '24 Sale 35.23 5,173 182,263 0 Sep 23 04:23 PM Leite John Chief Commercial Officer-CLIA Sep 04 '24 Sale 29.78 5,479 163,159 76,174 Sep 06 04:18 PM JOHN LEITE Officer Sep 04 '24 Proposed Sale 30.29 5,479 165,959 Sep 04 04:17 PM JONES EVAN/ FA Director Aug 13 '24 Option Exercise 10.41 8,486 88,339 54,800 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 27,188 875,565 5,173 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 20,457 658,801 34,343 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.00 101 3,031 32,361 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.01 99 2,971 46,314 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 09 '24 Option Exercise 10.41 300 3,123 47,445 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 1,032 30,990 46,413 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 746 22,402 32,462 Aug 13 04:38 PM Holstein Jens Director Aug 07 '24 Sale 29.00 5,000 145,000 27,878 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Option Exercise 10.41 1,214 12,638 50,288 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Sale 30.32 5,108 154,883 45,180 Aug 09 04:47 PM Evan Jones Director Aug 07 '24 Proposed Sale 27.05 59,904 1,620,403 Aug 07 07:52 PM EASTHAM KARIN Director Jul 16 '24 Sale 25.00 7,500 187,500 33,228 Jul 18 06:25 PM Leite John Chief Commercial Officer-CLIA Jul 16 '24 Sale 25.00 1,277 31,925 82,968 Jul 18 06:25 PM Holstein Jens Director Jul 16 '24 Sale 24.50 5,000 122,500 32,878 Jul 18 06:25 PM EASTHAM KARIN Director Jun 11 '24 Sale 20.59 3,870 79,683 29,255 Jun 13 04:24 PM Bhanji Muna Director Jun 10 '24 Sale 20.32 3,870 78,634 23,105 Jun 11 04:22 PM EASTHAM KARIN Director Jun 07 '24 Option Exercise 10.41 2,500 26,025 35,625 Jun 11 04:21 PM EASTHAM KARIN Director Jun 07 '24 Sale 20.97 2,500 52,425 33,125 Jun 11 04:21 PM Bhanji Muna Director May 28 '24 Sale 21.00 1,539 32,319 26,975 May 30 04:41 PM EASTHAM KARIN Director Apr 01 '24 Option Exercise 13.19 10,000 131,900 43,125 Apr 02 04:17 PM EASTHAM KARIN Director Apr 01 '24 Sale 21.65 10,000 216,528 33,125 Apr 02 04:17 PM JONES EVAN/ FA Director Mar 01 '24 Option Exercise 13.19 10,000 131,900 47,601 Mar 05 05:28 PM JONES EVAN/ FA Director Mar 01 '24 Sale 24.36 10,000 243,599 37,601 Mar 05 05:28 PM
Index RUT P/E - EPS (ttm) -1.35 Insider Own 14.31% Shs Outstand 57.76M Perf Week -1.78%
Market Cap 2.90B Forward P/E 449.86 EPS next Y 0.11 Insider Trans -5.39% Shs Float 50.17M Perf Month 12.97%
Income -78.58M PEG - EPS next Q -0.02 Inst Own 89.43% Short Float 7.36% Perf Quarter 15.38%
Sales 574.50M P/S 5.05 EPS this Y -2179.43% Inst Trans 2.77% Short Ratio 4.14 Perf Half Y -0.58%
Book/sh 7.44 P/B 6.67 EPS next Y 116.14% ROA -12.61% Short Interest 3.69M Perf Year -15.93%
Cash/sh 1.91 P/C 26.00 EPS next 5Y - ROE -17.72% 52W Range 36.73 - 67.13 Perf YTD -23.51%
Dividend Est. - P/FCF 540.42 EPS past 5Y 32.83% ROI -16.87% 52W High -26.02% Beta 0.96
Dividend TTM - Quick Ratio 1.40 Sales past 5Y 197.48% Gross Margin 84.75% 52W Low 35.20% ATR (14) 2.12
Dividend Ex-Date - Current Ratio 1.77 EPS Y/Y TTM -2268.65% Oper. Margin -5.58% RSI (14) 53.46 Volatility 4.12% 4.63%
Employees 1300 Debt/Eq 0.08 Sales Y/Y TTM 22.41% Profit Margin -13.68% Recom 1.75 Target Price 64.57
Option/Short Yes / Yes LT Debt/Eq 0.07 EPS Q/Q -682.78% Payout - Rel Volume 0.68 Prev Close 49.75
Sales Surprise 1.80% EPS Surprise 27.67% Sales Q/Q 21.39% Earnings Oct 28 AMC Avg Volume 891.93K Price 49.66
SMA20 -0.42% SMA50 8.75% SMA200 6.27% Trades
Volume 608,816 Change -0.18%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-18-24 Initiated Stifel
Hold
$50
Sep-03-24 Initiated Leerink Partners
Market Perform
$47
Aug-09-24 Initiated Deutsche Bank
Buy
$68
Jul-25-24 Initiated William Blair
Outperform
Jul-18-24 Downgrade Needham
Buy → Hold
Feb-29-24 Downgrade Piper Sandler
Overweight → Neutral
$85 → $55
Jan-23-24 Initiated Needham
Buy
$72
Jul-19-23 Initiated Robert W. Baird
Outperform
$79
Oct-12-22 Initiated Jefferies
Buy
$88
Sep-29-22 Initiated Berenberg
Buy
$85
Sep-13-22 Initiated Truist
Hold
$87
Jun-21-22 Initiated Piper Sandler
Overweight
$100
Mar-23-22 Resumed BofA Securities
Buy
$105
Dec-15-20 Upgrade Wells Fargo
Equal Weight → Overweight
$79
Nov-18-20 Initiated BTIG Research
Buy
$92
Oct-29-20 Upgrade Morgan Stanley
Equal-Weight → Overweight
$66 → $76
Sep-28-20 Initiated SVB Leerink
Outperform
$80
Jun-19-20 Initiated Canaccord Genuity
Buy
Jun-16-20 Initiated Wells Fargo
Equal Weight
$49
Jun-16-20 Initiated Morgan Stanley
Equal-Weight
$52
Show Previous Ratings
Nov-18-24 10:00AM
Nov-07-24 08:56AM
Nov-06-24 04:05PM
Nov-01-24 04:09AM
Oct-31-24 07:00AM
01:01PM
Loading…
Oct-29-24 01:01PM
11:56AM
Oct-28-24 05:55PM
04:05PM
Oct-21-24 01:00PM
10:00AM
Oct-15-24 08:00AM
Oct-09-24 03:24PM
Oct-07-24 04:06PM
04:05PM
04:59AM
Loading…
Sep-30-24 04:59AM
Sep-09-24 08:01AM
Sep-06-24 01:45AM
Aug-29-24 04:05PM
Aug-27-24 06:00AM
Aug-26-24 12:17PM
11:32AM
Aug-21-24 04:05PM
Aug-20-24 07:01PM
Aug-02-24 06:24AM
Jul-31-24 02:30PM
12:09PM
Jul-30-24 05:45PM
04:10PM
04:05PM
10:01AM
Loading…
Jul-23-24 10:01AM
Jul-18-24 07:01PM
07:01PM
Jul-16-24 07:20PM
04:05PM
Jul-11-24 01:37PM
Jul-09-24 08:31PM
06:33AM
Jul-08-24 04:15AM
Jul-06-24 04:09PM
Jul-04-24 07:35AM
Jul-03-24 04:07PM
Jul-02-24 10:56AM
Jul-01-24 05:45AM
Jun-30-24 03:00PM
Jun-29-24 07:02AM
Jun-27-24 01:31PM
Jun-26-24 11:06AM
07:48AM
Jun-24-24 02:27PM
Jun-21-24 05:45AM
Jun-20-24 07:02PM
Jun-18-24 03:15PM
Jun-17-24 02:44PM
Jun-13-24 07:16PM
Jun-10-24 01:44PM
Jun-07-24 01:17PM
Jun-06-24 01:03PM
Jun-04-24 08:05AM
Jun-03-24 04:59PM
May-31-24 12:26PM
03:15AM
May-30-24 04:00AM
May-28-24 03:03PM
May-27-24 11:14AM
May-23-24 12:22PM
08:00AM
07:04AM
02:00AM
May-21-24 01:56PM
May-20-24 03:38PM
03:40AM
May-18-24 02:36AM
May-17-24 11:10AM
May-15-24 07:41AM
May-14-24 08:15PM
May-07-24 12:20PM
May-06-24 07:00AM
May-04-24 02:30AM
May-03-24 05:49PM
12:02PM
May-02-24 04:07PM
May-01-24 12:19PM
10:59AM
07:42AM
(Thomson Reuters StreetEvents)
03:30AM
Apr-30-24 09:55PM
05:45PM
05:41PM
04:05PM
Apr-25-24 03:31PM
Apr-22-24 10:26AM
Apr-19-24 10:09AM
Apr-18-24 01:25PM
Apr-17-24 04:05PM
Apr-15-24 10:52AM
Apr-11-24 04:05PM
03:33PM
Apr-09-24 11:04AM
Apr-02-24 04:05PM
Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hykes Andrew President and CEO Nov 20 '24 Sale 50.83 3,000 152,490 442,310 Nov 22 04:56 PM Hoffman William Director Nov 18 '24 Sale 51.16 60,000 3,069,521 501,233 Nov 20 05:28 PM WILLIAM HOFFMAN Director Nov 18 '24 Proposed Sale 50.56 120,000 6,067,200 Nov 18 05:10 PM Hykes Andrew President and CEO Oct 29 '24 Sale 50.00 3,000 150,000 445,310 Oct 31 06:29 PM Hoffman William Director Oct 29 '24 Sale 50.05 40,000 2,002,000 561,233 Oct 31 06:21 PM ANDREW J HYKES Director Oct 29 '24 Proposed Sale 42.56 9,000 383,040 Oct 29 04:21 PM Hoffman William Director Oct 16 '24 Sale 45.02 40,000 1,800,835 601,233 Oct 18 05:40 PM Hoffman William Director Sep 16 '24 Sale 45.83 40,000 1,833,188 643,296 Sep 18 04:54 PM Hill, Mitch C. Chief Financial Officer Sep 12 '24 Option Exercise 0.46 3,000 1,371 182,600 Sep 13 04:35 PM Hill, Mitch C. Chief Financial Officer Sep 12 '24 Sale 45.13 3,000 135,385 179,600 Sep 13 04:35 PM MITCH HILL Officer Sep 12 '24 Proposed Sale 45.07 12,000 540,840 Sep 12 04:33 PM Hykes Andrew President and CEO Aug 20 '24 Sale 50.00 3,000 150,000 452,532 Aug 22 04:34 PM Hoffman William Director Aug 16 '24 Sale 48.89 40,000 1,955,751 703,296 Aug 20 04:32 PM Hoffman William Director Aug 19 '24 Sale 50.30 20,000 1,006,000 683,296 Aug 20 04:32 PM WILLIAM HOFFMAN Director Aug 19 '24 Proposed Sale 49.16 140,000 6,882,400 Aug 19 04:24 PM Hill, Mitch C. Chief Financial Officer Aug 12 '24 Option Exercise 0.46 5,000 2,285 184,600 Aug 14 05:10 PM Hill, Mitch C. Chief Financial Officer Aug 12 '24 Sale 47.99 5,000 239,964 179,600 Aug 14 05:10 PM Hykes Andrew President and CEO Jul 22 '24 Sale 55.23 3,000 165,690 455,252 Jul 24 05:04 PM Hoffman William Director Jul 16 '24 Sale 56.74 60,000 3,404,646 743,296 Jul 18 04:49 PM Tu Thomas Chief Medical Officer Jul 16 '24 Sale 55.16 3,480 191,957 309,777 Jul 18 04:46 PM Tu Thomas Chief Medical Officer Jul 15 '24 Sale 55.09 16,520 910,087 313,257 Jul 16 04:44 PM Hill, Mitch C. Chief Financial Officer Jul 12 '24 Option Exercise 0.46 5,000 2,285 184,227 Jul 16 04:40 PM Hill, Mitch C. Chief Financial Officer Jul 12 '24 Sale 53.95 5,000 269,759 179,227 Jul 16 04:40 PM Hoffman William Director Jul 01 '24 Sale 50.15 20,000 1,003,000 805,359 Jul 03 03:07 PM Hykes Andrew President and CEO Jul 01 '24 Sale 50.08 3,000 150,240 462,474 Jul 03 03:04 PM Chambers Rebecca Director Jun 21 '24 Sale 45.99 260 11,957 9,684 Jun 24 05:48 PM Hoffman William Director Jun 17 '24 Sale 43.54 40,000 1,741,579 825,359 Jun 20 04:39 PM Hill, Mitch C. Chief Financial Officer Jun 12 '24 Option Exercise 0.46 5,000 2,285 186,294 Jun 14 04:52 PM Hill, Mitch C. Chief Financial Officer Jun 12 '24 Sale 47.60 5,000 237,977 181,294 Jun 14 04:52 PM Hykes Andrew President and CEO May 28 '24 Sale 50.00 3,000 150,000 465,474 May 30 07:14 PM Hoffman William Director May 28 '24 Sale 50.13 60,000 3,007,800 865,359 May 30 07:10 PM Chambers Rebecca Director May 20 '24 Sale 45.39 964 43,756 9,944 May 21 06:57 PM Hoffman William Director May 16 '24 Sale 46.60 40,000 1,863,977 925,359 May 17 06:07 PM Hill, Mitch C. Chief Financial Officer May 13 '24 Option Exercise 0.46 6,000 2,742 187,294 May 15 04:39 PM Hill, Mitch C. Chief Financial Officer May 13 '24 Sale 45.97 6,000 275,812 181,294 May 15 04:39 PM Hoffman William Director May 01 '24 Sale 42.00 38,549 1,619,047 965,359 May 03 05:40 PM Hoffman William Director Apr 16 '24 Sale 40.00 1,451 58,040 999,782 Apr 18 06:38 PM Hill, Mitch C. Chief Financial Officer Apr 12 '24 Option Exercise 0.46 6,000 2,742 187,294 Apr 16 04:32 PM Hill, Mitch C. Chief Financial Officer Apr 12 '24 Sale 40.96 6,000 245,760 181,294 Apr 16 04:32 PM Hoffman William Director Mar 18 '24 Sale 41.13 40,000 1,645,079 1,003,296 Mar 20 04:34 PM Hill, Mitch C. Chief Financial Officer Mar 12 '24 Option Exercise 0.46 6,000 2,742 189,361 Mar 14 04:31 PM Hill, Mitch C. Chief Financial Officer Mar 12 '24 Sale 41.91 6,000 251,461 183,361 Mar 14 04:31 PM Hoffman William Director Dec 15 '23 Sale 65.08 25,000 1,627,073 1,045,493 Dec 19 05:18 PM Hill, Mitch C. Chief Financial Officer Dec 12 '23 Option Exercise 0.46 6,500 2,970 176,730 Dec 14 04:35 PM Hill, Mitch C. Chief Financial Officer Dec 12 '23 Sale 62.75 6,500 407,855 170,230 Dec 14 04:35 PM Hoffman William Director Dec 04 '23 Option Exercise 0.43 103,492 44,336 1,070,493 Dec 06 05:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
